Related Experiment Video

Updated: Jul 13, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Therapeutic options for systemic sclerosis

S M Akerkar1, L S Bichile

  • 1Dept. of Rheumatology, Seth GS Medical College and KEM Hospital, Mumbai.

Indian Journal of Dermatology, Venereology and Leprology
|July 24, 2007
PubMed

Insights

Systemic sclerosis treatment requires a combined approach targeting vascular damage, immune activation, and fibrogenesis. Angiotensin blockade and cyclophosphamide show promise, improving survival and managing alveolitis in systemic sclerosis patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Biology

Background:

  • Systemic sclerosis is a rare connective tissue disease with complex pathophysiology.
  • Key features include vascular damage, immune cell activation, and excessive fibrogenesis.
  • These distinct pathological processes may necessitate multifaceted therapeutic strategies.

Purpose of the Study:

  • To review current therapeutic strategies for systemic sclerosis.
  • To assess the efficacy of various treatments, including combination therapies.
  • To highlight the importance of individualized treatment approaches.

Main Methods:

  • Critical assessment of clinical trial data for systemic sclerosis therapies.
  • Review of evidence for specific drug classes, such as angiotensin receptor blockers and cyclophosphamide.
  • Exploration of emerging therapeutic targets, including cytokine modulators.

Main Results:

  • Angiotensin blockade significantly improves survival and prevents renal crisis in systemic sclerosis.
  • Cyclophosphamide is definitively effective for treating associated alveolitis.
  • Ongoing research explores novel agents targeting cytokines.

Conclusions:

  • Current systemic sclerosis therapy is evolving but not yet perfect.
  • Combination therapy offers a more promising approach than single-agent treatment.
  • Individualized treatment based on disease stage, subset, and organ involvement is crucial for effective management.

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...